IDH3A and liver cancer: For example, loss of SDHA enabling the utilization of glutamine as a fuel for the TCA cycle sensitizes AML cells towards venetoclax, a FDA-approved BCL-2 inhibitor [30], while overexpression of IDH3A, the third member of the isocitrate dehydrogenases (IDHs) family, has been associated with poor survival in breast cancer and liver cancer [31].